Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients). The Probuphine and placebo arms will be double blinded, while the Suboxone arm will be open-label… (Source: Health News from Medical News Today)

Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients). The Probuphine and placebo arms will be double blinded, while the Suboxone arm will be open-label… (Source: Health News from Medical News Today)

Updated Date: Mar 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Mar 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Conclusions  Prior history of incarceration does not appear to impact primary care office-based treatment of opioid dependence with buprenorphine/naloxone.
Community health care providers can be reassured that initiating buprenorphine/naloxone in opioid dependent individuals with
a history of incarceration will have similar outcomes as those without this history.

Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s11606-010-1306-0Authors
Emily A. Wang, Yale University School of Medicine Department of Internal Medicine New Haven CT USABrent A. Moore, Yale University School of Medicine Department of Psychiatry New Haven CT USALynn E. Sullivan, Yale University School of Medicine Department of Internal Medicine New Haven CT USADavid A. Fiellin, Yale Univers…

Conclusions  Prior history of incarceration does not appear to impact primary care office-based treatment of opioid dependence with buprenorphine/naloxone.
Community health care providers can be reassured that initiating buprenorphine/naloxone in opioid dependent individuals with
a history of incarceration will have similar outcomes as those without this history.

Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s11606-010-1306-0Authors
Emily A. Wang, Yale University School of Medicine Department of Internal Medicine New Haven CT USABrent A. Moore, Yale University School of Medicine Department of Psychiatry New Haven CT USALynn E. Sullivan, Yale University School of Medicine Department of Internal Medicine New Haven CT USADavid A. Fiellin, Yale Univers…

In conclusion, buprenorphine overdose causes an opioid syndrome clinically indistinguishable from heroin and methadone. Although mental status and respiratory depression are often unresponsive to low-dose naloxone, flumazenil may be effective in buprenorphine overdoses involving benzodiazepines. (Source: Journal of Substance Abuse Treatment)